Ultragenyx Pharmaceutical Inc. (RARE)
- Previous Close
44.28 - Open
43.41 - Bid 42.82 x 200
- Ask 44.29 x 200
- Day's Range
43.22 - 43.41 - 52 Week Range
31.52 - 54.98 - Volume
5,116 - Avg. Volume
701,833 - Market Cap (intraday)
3.558B - Beta (5Y Monthly) 0.66
- PE Ratio (TTM)
-- - EPS (TTM)
-8.25 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
89.40
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
www.ultragenyx.comRecent News: RARE
Performance Overview: RARE
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RARE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RARE
Valuation Measures
Market Cap
3.65B
Enterprise Value
3.11B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.50
Price/Book (mrq)
13.24
Enterprise Value/Revenue
7.17
Enterprise Value/EBITDA
-6.03
Financial Highlights
Profitability and Income Statement
Profit Margin
-139.70%
Return on Assets (ttm)
-23.43%
Return on Equity (ttm)
-193.23%
Revenue (ttm)
434.25M
Net Income Avi to Common (ttm)
-606.64M
Diluted EPS (ttm)
-8.25
Balance Sheet and Cash Flow
Total Cash (mrq)
577.21M
Total Debt/Equity (mrq)
339.39%
Levered Free Cash Flow (ttm)
-312.22M
Research Analysis: RARE
Company Insights: RARE
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: RARE
Daily – Vickers Top Buyers & Sellers for 10/17/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 04/20/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 10/15/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.